
    
      The trial is a randomized, double blind, placebo controlled, parallel group trial in subjects
      diagnosed with fibromyalgia in accordance with the American College of Rheumatology. Total
      duration is up to twenty-one (21) weeks of trial participation. Subjects will undergo a
      screening and withdrawal/washout period lasting up to five (5) weeks combined, followed by
      baseline period lasting one (1) week. Total treatment duration will be fourteen (14) weeks
      followed by one (1) week safety follow-up post treatment period. During the screening and
      withdrawal/washout period, no study medication will be given; however rescue medication
      acetaminophen (up to 4 grams per day) will be allowed.
    
  